Kawasaki, Japan

Tomohisa Ninomiya


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tomohisa Ninomiya: Innovator in Therapeutic Agents for Inflammatory Bowel Diseases

Introduction

Tomohisa Ninomiya is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of medicine, particularly in the development of therapeutic agents for inflammatory bowel diseases. His innovative approach has the potential to improve treatment outcomes for patients suffering from these conditions.

Latest Patents

Ninomiya holds a patent for a therapeutic agent aimed at treating inflammatory bowel diseases. The patent describes a method for maintaining remission or treating these diseases by administering a therapeutically effective amount of 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzoazepine, or its prodrug. This method is particularly effective in maintaining therapy and has minimal side effects, even in severe cases resistant to conventional treatments. He has 1 patent to his name.

Career Highlights

Ninomiya is associated with Meiji Seika Kaisha, Ltd., where he continues to work on innovative solutions in the pharmaceutical industry. His research focuses on developing effective treatments that can significantly enhance the quality of life for patients with chronic conditions.

Collaborations

Throughout his career, Ninomiya has collaborated with esteemed colleagues such as Takashi Shishikura and Mitsuhiro Uchida. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Tomohisa Ninomiya's work in developing therapeutic agents for inflammatory bowel diseases showcases his commitment to advancing medical science. His innovative methods and collaborations highlight the importance of research in improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…